Back to News
Market Impact: 0.3
Biohaven Licenses IgG Degrader Portfolio To Ono Pharma In Key Asian Markets
Source: Nasdaq
Healthcare & BiotechM&A & RestructuringCompany Fundamentals
Biohaven entered a strategic licensing and collaboration agreement granting Ono Pharmaceutical exclusive rights to develop and commercialize Biohaven’s MoDE pan-IgG degrader portfolio in Japan, South Korea and Taiwan. The article excerpt provides no financial terms or further details on the collaboration.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
BHVN0.65
More News
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- Verizon stock heads for worst day since 2002 as SpaceX U.S. network plans whack telcos
- SpaceX to buy key spectrum that could help Starlink Mobile become major US cell carrier
- Why is the Chinese stock market missing the AI rally
- OpenAI's revenue scare, Delta earnings, what investors think of a Starbucks-Chipotle deal and more in Morning Squawk
- Why is T-Mobile stock tumbling today?